VOLUME 63 2002 NUMBER 2
CME Pretest 92
CME Posttest 172
Brainstorms
93 Antipsychotic Polypharmacy: Squandering Precious Resources?
Stephen M. Stahl
[PDF]
Original Articles
95 What Role Do Atypical Antipsychotic Drugs Have in
Treatment-Resistant Depression? Michael E. Thase
[Abstract]
[PDF]
104 Obsessive-Compulsive Symptoms
During Treatment With Olanzapine and Risperidone:
A Prospective Study of 113 Patients With Recent-Onset
Schizophrenia or Related DisordersLieuwe de Haan, M.D.; Nico Beuk, M.D.;
Britt Hoogenboom, M.D.; Peter Dingemans, Ph.D.;
and Don Linszen, M.D., Ph.D.
[Abstract]
[PDF]
108 Comparison Between the Effects of Atypical and Traditional
Antipsychotics on Work Status for Clients in a Psychiatric
Rehabilitation Program. [CME] Piper
S. Meyer, Gary R. Bond, Sandra L. Tunis, and Marion L. McCoy
[Abstract]
[PDF]
117 No Weight Gain Among Elderly Schizophrenia Patients After
1 Year of Risperidone Treatment. Yoram Barak
[Abstract]
[PDF]
120 Demographic and Clinical Characteristics of Individuals in
a Bipolar Disorder Case Registry. [CME]
David J. Kupfer, Ellen Frank, Victoria J. Grochocinski,
Patricia A. Cluss, Patricia R. Houck, and Debra A. Stapf
[Abstract]
[PDF]
126 Current Comorbidity of Psychiatric Disorders Among DSM-IV
Major Depressive Disorder Patients in Psychiatric Care in the
Vantaa Depression Study. Tarja K. Melartin, Heikki J. Rytsala,
Ulla S. Leskela, Paula S. Lestela-Mielonen, T. Petteri Sokero,
and Erkki T. Isometsa
[Abstract]
[PDF]
135 Hepatotoxicity Associated With the New Antidepressants. Alfonso
Carvajal Garcia-Pando, Javier Garcia del Pozo, Ana Sanchez
Sanchez, Alfonso Velasco Martin, Ana Maria Rueda de Castro, and
M. Isabel Lucena
[Abstract]
[PDF]
138 Behavior Therapy for Obsessive-Compulsive Disorder Guided
by a Computer or by a Clinician Compared With Relaxation as a
Control. John H. Greist, Isaac M. Marks, Lee Baer, Kenneth A.
Kobak, Keith W. Wenzel, M. Joyce Hirsch, Julia M. Mantle, and
Cathryn M. Clary
[Abstract]
[PDF]
146 Stabilization of Mood From Below Versus Above Baseline in
Bipolar Disorder: A New Nomenclature. Terence A. Ketter and
Joseph R. Calabrese
[Abstract]
[PDF]
152 Predictors of Response to Pharmacotherapy in Social
Anxiety Disorder: An Analysis of 3 Placebo-Controlled Paroxetine
Trials. Dan J. Stein, Murray B. Stein, Cornelius D. Pitts,
Rajinder Kumar, and Brian Hunter
[Abstract]
[PDF]
156 Duration of Therapy and Health Care Costs of Fluoxetine,
Paroxetine, and Sertraline in 6 Health Plans. Daniel Polsky,
Peter Onesirosan, Mark S. Bauer, and Henry A. Glick
[Abstract]
[PDF]
Letters to the Editor
165 Organic Hypomania Secondary to Sibutramine-Citalopram Interaction. Franco
Benazzi
[PDF]
166 Risperidone-Induced Pisa Syndrome. Kenichi Harada,
Nobuyuki Sasaki, Hiroshi Ikeda, Norihito Nakano, Hiroki Ozawa,
and Toshikazu Saito
[PDF]
166 Interferon-Induced Depression Treated With Citalopram. Andy
Farah
[PDF]
167 Clozapine and Tardive Dyskinesia. Richard Kumet and
Marlene P. Freeman
[PDF]
168 Role of Receptor Binding Profiles in
Antidepressant-Induced Sexual Dysfunction. Egon Michael
Haberfellner
[PDF]
- Reply by Angel L. Montejo
169 Olanzapine for the Treatment of Monosymptomatic
Hypochondriacal Psychosis. Robert G. Fawcett
[PDF]
169 Retraction. Feifel D, Moutier CY, Perry W. Safety
and tolerability of a rapidly escalating dose-loading regimen for
risperidone (J Clin Psychiatry 2000;61:909-911)
[PDF]
Book Reviews 170
NOW@Psychiatrist.com 174
Information for authors
see January 2002, pages 83-85 or our Web site at www.psychiatrist.com/author.htm